Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10383572" target="_blank" >RIV/00216208:11130/18:10383572 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/18:00105799 RIV/00216208:11140/18:10383572 RIV/00216208:11150/18:10383572 RIV/61989592:15110/18:73590150 a 5 dalších

Výsledek na webu

<a href="http://dx.doi.org/10.21873/anticanres.13048" target="_blank" >http://dx.doi.org/10.21873/anticanres.13048</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.13048" target="_blank" >10.21873/anticanres.13048</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Popis výsledku v původním jazyce

Aim: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan- Meier method and Cox analysis. Results: Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. Conclusion: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment.

Název v anglickém jazyce

Chronic Inflammation as a Potential Predictive Factor of Nivolumab Therapy in Non-small Cell Lung Cancer

Popis výsledku anglicky

Aim: To investigate potential associations between clinical and standard peripheral blood biomarkers and clinical outcome in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. Patients and Methods: A total of 120 patients with advanced NSCLC treated at seven comprehensive cancer care centers were analyzed in this national retrospective study. Survival statistics were evaluated using the Kaplan- Meier method and Cox analysis. Results: Among clinical parameters, histology was significantly associated with progression-free survival. Univariate Cox-proportional hazards model indicated prognostic and predictive role of a panel of laboratory parameters reflecting chronic inflammatory pattern (elevated neutrophil count, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, C-reactive protein and decrease in hemoglobin and albumin). Higher serum calcium concentration was also associated with nivolumab treatment effect. Conclusion: Tumor histology was the only clinical parameter predicting the outcome of nivolumab treatment.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30203 - Respiratory systems

Projekt

<a href="/cs/project/NV17-30748A" target="_blank" >NV17-30748A: Nová metoda kombinace funkčních zobrazovacích metod a nádorové genomiky pro neinvazivní fenotypizaci a sledování efektu léčby plicních karcinomů</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

12

Strana od-do

6771-6782

Kód UT WoS článku

000451742800023

EID výsledku v databázi Scopus

2-s2.0-85057557743